CytomX Therapeutics to Launch Phase 1 Varseta-M Combination Study in Colorectal Cancer
I'm PortAI, I can summarize articles.
CytomX Therapeutics Inc. is set to launch a Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer in Q1 2026, with initial data expected in H1 2027. The company will also present Phase 1 expansion data for CX-2051 in Q1 2026 and anticipates initial Phase 1 combination data for CX-801 with KEYTRUDA® in melanoma by the end of 2026. Updates will be shared at the 44th Annual JP Morgan Healthcare Conference on January 14, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments